Attovia Therapeutics, Inc.

Attovia Therapeutics, Inc.'s next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, Attovia Therapeutics, Inc. has 43.03M shares outstanding.

As of June 30, 2026, Attovia Therapeutics, Inc. maintains a current ratio of 9.39, meaning it holds 9.4x the short-term assets needed to cover near-term liabilities.

As of the close on October 22, 2026, Attovia Therapeutics, Inc.'s stock has gained approximately 2975.29% over the past 52 weeks. The 50-day moving average sits at 19.44, while the 200-day moving average is 7.18.

These figures cover the twelve months ended June 30, 2026.

As of June 30, 2026, Attovia Therapeutics, Inc. holds 115.13M in cash and equivalents against 4.33M in total debt, resulting in a net debt position of -32.83M. Total book value stands at -145.46M, with working capital of 105.79M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026. After subtracting -73,000.00 in capital expenditures, free cash flow totaled -16.86M - equivalent to -0.39 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -4,845.11 and net profit margin of -4,597.11 provide insight into operational efficiency.